Clinical Trials · NCT03985384
Semaglutide Treatment On Coronary Progression
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Enrollment
- 140
- Start date
- Apr 2019
- Locations
- 1 site, United States
- Primary endpoint
- Rate of change in non-calcified plaque volume